Evidence map›Paper›PMID 41178457›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Metallothionein-Inspired Asymmetric Heteroatom Doping of Single-Atom Nanozymes for Multi-Enzyme Biocatalysis.

Kaijuan Chen, Qianfan Chen, Bernt Johannessen, Chun-Ho Lin, Long Hu, Kang Liang, Jieying Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kaijuan ChenSchool of Chemical Engineering, Australian Centre for NanoMedicine, The University of New South Wales, Sydney, NSW, 2052, Australia.
Qianfan ChenGraduate School of Biomedical Engineering, The University of New South Wales, Sydney, NSW, 2052, Australia.
Bernt JohannessenAustralian Synchrotron, ANSTO, Clayton, Victoria, 3168, Australia.
Chun-Ho LinSchool of Materials Science and Engineering, University of New South Wales (UNSW), Sydney, NSW, 2052, Australia.
Long HuSchool of Materials Science and Engineering, University of New South Wales (UNSW), Sydney, NSW, 2052, Australia.
Kang LiangSchool of Chemical Engineering, Australian Centre for NanoMedicine, The University of New South Wales, Sydney, NSW, 2052, Australia.
Jieying LiangSchool of Chemical Engineering, Australian Centre for NanoMedicine, The University of New South Wales, Sydney, NSW, 2052, Australia.ORCID https://orcid.org/0000-0003-1959-9917

Funding

Australian Research Council DP250101401Australian Research Council FT220100479National Health and Medical Research Council 2026262
6 · The paper itself

Abstract

Single-atom catalysts (SACs) exhibit enzyme-mimicking activity but are often limited by single-enzyme-like functions and modest catalytic efficiency. Here, a metallothionein-inspired heteroatom doping strategy is reported to construct asymmetric Fe single-atom catalysts (FeN

Indexed as

MetallothioneinBiocatalysisIronMetal-Organic FrameworksIronMetallothioneinMetal-Organic Frameworksbiocatalysisbiomineralizationmetal‐organic frameworksnanozymessingle atom catalysts

Identifiers

PMID41178457
PMCPMC12850297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.